Quick Answer
Black Diamond Therapeutics, Inc. reported Total Assets of $143.01 million for the year ending 2025.
- Black Diamond Therapeutics, Inc. showed an increase of +16.6% in Total Assets from 2024 to 2025.
- This data is from Black Diamond Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $362.80 million | Q2 2020: $349.45 million | Q3 2020: $346.44 million | Q1 2021: $313.26 million | Q2 2021: $287.88 million | Q3 2021: $274.13 million | Q1 2022: $219.48 million | Q2 2022: $198.83 million | Q3 2022: $180.42 million | Q1 2023: $135.58 million | Q2 2023: $119.88 million | Q3 2023: $172.38 million | Q1 2024: $142.52 million | Q2 2024: $149.99 million | Q3 2024: $137.90 million | Q1 2025: $176.25 million | Q2 2025: $166.39 million | Q3 2025: $157.73 million.
- Over the full 8 years of available data (2018 to 2025), Black Diamond Therapeutics, Inc.'s Total Assets has grown by 175.9%.
- Historical annual values: Fiscal year 2025: $143.01 million | Fiscal year 2024: $122.64 million | Fiscal year 2023: $158.57 million | Fiscal year 2022: $156.26 million | Fiscal year 2021: $247.68 million | Fiscal year 2020: $329.67 million | Fiscal year 2019: $158.30 million | Fiscal year 2018: $51.83 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: